"Dyslipidemias" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Abnormalities in the serum levels of LIPIDS, including overproduction or deficiency. Abnormal serum lipid profiles may include high total CHOLESTEROL, high TRIGLYCERIDES, low HIGH DENSITY LIPOPROTEIN CHOLESTEROL, and elevated LOW DENSITY LIPOPROTEIN CHOLESTEROL.
| Descriptor ID |
D050171
|
| MeSH Number(s) |
C18.452.584.500
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Dyslipidemias".
Below are MeSH descriptors whose meaning is more specific than "Dyslipidemias".
This graph shows the total number of publications written about "Dyslipidemias" by people in this website by year, and whether "Dyslipidemias" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2005 | 2 | 2 | 4 |
| 2006 | 5 | 0 | 5 |
| 2007 | 2 | 2 | 4 |
| 2008 | 5 | 1 | 6 |
| 2009 | 4 | 1 | 5 |
| 2010 | 5 | 2 | 7 |
| 2011 | 9 | 4 | 13 |
| 2012 | 7 | 1 | 8 |
| 2013 | 9 | 2 | 11 |
| 2014 | 5 | 1 | 6 |
| 2015 | 7 | 6 | 13 |
| 2016 | 7 | 5 | 12 |
| 2017 | 5 | 1 | 6 |
| 2018 | 12 | 1 | 13 |
| 2019 | 19 | 0 | 19 |
| 2020 | 10 | 2 | 12 |
| 2021 | 6 | 4 | 10 |
| 2022 | 6 | 0 | 6 |
| 2023 | 4 | 0 | 4 |
| 2024 | 2 | 1 | 3 |
| 2025 | 6 | 0 | 6 |
| 2026 | 3 | 0 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Dyslipidemias" by people in Profiles.
-
2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2026 May 19; 87(19):2624-2757.
-
2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2026 Apr 28; 153(17):e1154-e1276.
-
Intracoronary Imaging and Transcriptomic Characteristics Before and After Maximum Lipid-Lowering Therapy: YELLOW-III Study of Evolocumab and Maximum Statin Therapy in Chronic Coronary Disease. JACC Cardiovasc Imaging. 2026 Apr; 19(4):516-534.
-
A multicenter trial to test pitavastatin calcium in youth with combined dyslipidemia of obesity: Design, implementation, challenges, and responses. Am Heart J. 2026 Apr; 294:107327.
-
Genome-wide gene-sleep interaction study identifies novel lipid loci in 732,564 participants. Atherosclerosis. 2026 Jan; 412:120603.
-
The evolving landscape of targets for lipid lowering: from molecular mechanisms to translational implications. Eur Heart J. 2025 Nov 21; 46(44):4737-4750.
-
Genetic Contribution to Treatment-Related Dyslipidemia in Adult Survivors of Childhood Cancer: Findings from the CCSS, SJLIFE, and DCCSS-LATER Cohorts. Cancer Epidemiol Biomarkers Prev. 2025 Nov 03; 34(11):2068-2076.
-
Visit-to-visit lipid variability, coronary artery calcification, inflammation, and mortality in the Multi-Ethnic Study of Atherosclerosis. Eur J Prev Cardiol. 2025 Sep 22; 32(13):1235-1244.
-
Cardiovascular Outcomes With Icosapent Ethyl by Baseline Low-Density Lipoprotein Cholesterol: A Secondary Analysis of the REDUCE-IT Randomized Trial. J Am Heart Assoc. 2025 Mar 04; 14(5):e038656.
-
Does Adopting Western Low-density Lipoprotein Cholesterol Targets Expose Indians to a Higher Risk of Cardiovascular Events? Expert Opinion From the Lipid Association of India. J Assoc Physicians India. 2024 Oct; 72(10):71-76.